<DOC>
	<DOC>NCT00884546</DOC>
	<brief_summary>To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.</brief_summary>
	<brief_title>Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis of Multiple Myeloma Men and Women at least 18 years old ECOG status 02 Last therapeutic or diagnostic treatment at least 21 days prior Bone marrow transplants must have been completed at least 3 months prior Any toxicity from prior therapies must have resolved to Grade â‰¤1 Women pregnant or breastfeeding WOCBP unwilling/unable to use acceptable method to avoid pregnancy Uncontrolled medical disorder or active infection Current or recent (w/in 3 months) gastrointestinal disorder Inability to swallow oral medication Inability to be venipunctured Uncontrolled or significant cardiovascular disease Uncontrolled hyperlipidemia Intolerance of lenalidomide or bortezomib if participating in Arms B and C Concurrent therapy with any other investigational product Subjects involuntary incarcerated Subjects detained for treatment of psychiatric or physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>